Impact of 26 Skin Diseases on the Risk of Non-Small

2	Cell Lung	Cancer: A	A Mend	lelian F	Rand	lomi	izat	ion	Stud	ly
---	-----------	-----------	--------	----------	------	------	------	-----	------	----

3	Using	FinnGen	ı R11 Data
---	-------	---------	------------

4	Xingyuan Li ¹
5	Hui Li ²
6	
7	¹ Hunan University of Chinese Medicine, Changsha, Hunan, China 410208;
8	² Hunan University of Chinese Medicine Affiliated Hospital of Changde, Changde
9	Hunan, China 415000
10	
11	Xingyuan Li 1*
12	Hui Li ^{2*}
13	*These authors contributed equally to this work
14	
15	Correspondence: Hui Li
16	Hunan University of Chinese Medicine Affiliated Hospital of Changde, Changde,
17	Hunan, China 415000
18	Email: 786802170@qq.com
19	
20	
21	

23 Abstract: 24 Purpose: To determine whether genetic predisposition to various skin diseases influences the 25 risk of non-small cell lung cancer (NSCLC) through Mendelian randomization (MR). 26 Methods: Single nucleotide polymorphisms (SNPs) associated with 26 skin diseases were 27 extracted from the FinnGen R11 dataset and underwent rigorous quality control. To evaluate the 28 association between these skin diseases and the risk of non-small cell lung cancer (NSCLC), we 29 applied several analytical methods, including inverse-variance weighted (IVW), MR-Egger 30 regression, weighted median, Simple mode, and Weighted mode. The robustness of the findings 31 was further supported by assessing SNP heterogeneity with the Cochran Q test and evaluating 32 horizontal pleiotropy using the MR-Egger intercept test. 33 Results: Our study revealed that genetically predicted dermatitis herpetiformis (DH) was 34 significantly associated with an elevated risk of squamous cell carcinoma of the lung (SCC). Acne 35 was nominally linked to an increased risk of SCC. Additionally, rhinophyma (RHN), hidradenitis 36 suppurativa (HS), and DH were nominally associated with a higher risk of adenocarcinoma of the 37 lung (ADC). Of the remaining 22 skin diseases analyzed, 7 lacked sufficient instrumental 38 variables to meet inclusion criteria. The other 15 skin diseases showed no statistically significant 39 association with NSCLC. 40 Conclusion: This study ultimately analyzed the relationship between 19 skin diseases and 41 NSCLC at the genetic level, while 7 other skin diseases could not be analyzed due to insufficient 42 instrumental variables. Dermatitis herpetiformis and acne were associated with an increased risk 43 of squamous cell carcinoma of the lung. Additionally, rhinophyma, hidradenitis suppurativa, and 44 dermatitis herpetiformis were associated with an increased risk of adenocarcinoma of the lung. 45 Keywords: [Skin Diseases, Genetic level, Non-Small Cell Lung Cancer, Mendelian 46 randomization] 47

1.Introduction

- Lung cancer is one of the most prevalent and deadly cancers worldwide [1]. Non-small 48 49
 - cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases, highlighting the

need for targeted research and therapies. The most common NSCLC subtypes are 50 adenocarcinoma (ADC) and squamous cell carcinoma (SCC), representing 40% and 25-51 30% of cases, respectively [2]. The development and progression of NSCLC are 52 influenced by genetic susceptibility, environmental factors, chronic inflammation, and 53 immune system dysregulation [3]. Despite extensive research, the etiology and 54 55 pathogenesis of lung cancer remain incompletely understood [4]. Skin diseases are a group of conditions that affect the skin, hair, nails, and associated 56 tissues. Several studies have already explored the physiological and pathological 57 58 connections between the skin and lungs, particularly focusing on the shared roles of certain inflammatory pathways in lung and skin inflammation, as well as the relationship 59 between inflammation and lung tumors [5]-[7], However, there are still many deficiencies 60 in the research on the correlation between specific skin diseases and lung diseases. 61 Previous Mendelian Randomization (MR) studies have also confirmed the association 62 between psoriasis and the risk of lung cancer [8]-[9], Additionally, a Mendelian 63 randomization study demonstrated a relationship between psoriasis and pulmonary 64 fibrosis [10]. Building on these studies, it is logical to further investigate the relationship 65 between lung cancer and a broader range of skin diseases. 66 67 Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for lung cancer often lead to varying degrees of adverse reactions in the skin and mucous 68 membranes [10]-[11]. Therefore, in a clinical setting, it is challenging to accurately observe 69 the relationship between skin diseases and lung cancer without these confounding factors. 70 The MR method uses genetic variants as instrumental variables to mitigate confounding 71 factors and provide stronger evidence of causal relationships [12]. Unlike clinical trials, 72

- 73 MR can eliminate the influence of social environmental factors and treatment-related
- effects on study results [13]-[14], making it an effective tool for studying the genetic links
- 75 between skin diseases and lung cancer.

77

78

82

2. Information and methodology

2.1. Sources of information

- 79 To utilize the most recent research data and ensure the uniformity of the study population, we
- 80 chose to obtain the instrumental variables from the June 2024 R11 data of the FinnGen database
- 81 (index (finngen.fi)). The final selected dataset is detailed in Table1.

2.2. Assumptions of the MR study

- 83 The Mendelian Randomization (MR) study is grounded in three key assumptions that ensure valid
- 84 causal inferences [15]. First, the relevance assumption requires that genetic instrumental variables
- 85 (GIVs) are strongly associated with the exposure factors. Second, the independence assumption
- 86 requires that GIVs are isolated from any confounders that might impact the correlation between
- 87 GIVs and outcomes. Third, the exclusion restriction assumption mandates that GIVs influence
- 88 outcomes solely through the exposure factors, with no direct impact on the outcomes themselves
- 89 (Fig1). In this study, skin diseases are considered the primary exposure factors, with squamous
- 90 cell carcinoma (SCC) and adenocarcinoma (ADC) of the lung as the outcomes of interest. The
- objective is to analyze the potential causal impact of skin diseases on these two major subtypes
- 92 of non-small cell lung cancer (NSCLC).

2. 3. Screening for genetic instrumental variables

- 94 A stringent threshold of $P < 5 \times 10^{-8}$ was used to identify single nucleotide polymorphisms
- 95 (SNPs) significantly associated with exposure factors, qualifying them as genetic instrumental

variables (GIVs). This threshold selects only the most statistically significant SNPs, enhancing the reliability of the Mendelian Randomization (MR) analysis. To minimize confounding from linkage disequilibrium (LD), an r^2 value of 0.001 and a genetic window of 10,000 kilobases (kb) were applied. The strength of the GIVs was evaluated using the F statistic, calculated as $F = (beta/se)^{2[16]}$. An F value below 10 indicates a weak instrumental variable, potentially compromising the MR analysis. Therefore, only SNPs with adequate F values were retained. If the initial threshold of $P < 5 \times 10^{-8}$ did not yield enough SNPs, it was relaxed to $P < 5 \times 10^{-6}$ [17] to ensure sufficient genetic variants for analysis, especially for less common exposures. Despite this adjustment, 7 skin diseases still lacked enough instrumental variables and were excluded from the analysis.

2. 4. Statistical analysis

The study employed a range of advanced statistical methods, including Inverse Variance Weighted (IVW), MR-Egger regression, Weighted Median, Simple mode, and Weighted mode, to investigate the causal relationship between various skin diseases and non-small cell lung cancer (NSCLC). These methods provided a comprehensive analysis of potential genetic associations. The IVW method was used to estimate the overall causal effect by combining the effects of all selected SNPs, assuming no pleiotropy among genetic variants [18]. MR-Egger regression, by relaxing the no-pleiotropy assumption, accounted for possible biases by allowing some instrumental variables to influence the outcome through pathways other than the exposure [19], The Weighted Median method, which requires that at least 50% of the total weight from genetic variants be valid [20]. The Simple mode method offered stable estimates when dealing with a small number of instrumental variables, while the Weighted mode method reduced bias caused by heterogeneous effects among genetic variants [21]. Cochran's Q test assessed heterogeneity among SNPs, with a P < 0.05 indicating the presence of heterogeneity, suggesting that genetic variants may not be uniformly associated with the exposure or outcome. MR-Egger regression was also used to test for horizontal and directional pleiotropy, with SNPs causing significant

pleiotropy (P < 0.05) being excluded to prevent bias [22]. Finally, A leave-one-out analysis was conducted to systematically exclude each SNP individually, assessing the influence of each on the overall association between exposure and outcome, ensuring no single SNP disproportionately influenced the results. **Results** 3.1. Instrumental variable In the dataset of 26 skin diseases selected for this study, 7 datasets still could not obtain sufficient instrumental variables even after lowering the inclusion and exclusion criteria. For 9 datasets, instrumental variables could only be obtained according to the reduced criterion of P < 5 × 10−6. The remaining 10 datasets were able to obtain instrumental variables according to the general standard. Among these, the number of instrumental variables for the skin diseases that vielded positive results were as follows: Dermatitis herpetiformis: 6 Acne: 5 Hidradenitis suppurativa: 3 Rhinophyma: 4 Notably, Rhinophyma could only obtain instrumental variables after lowering the significance threshold to P < 5 × 10-6, whereas the SNPs used for the other positive results all met the criteria before the reduction. The positive results of the MR analysis are presented in Table 3, while the heterogeneity and horizontal pleiotropy tests are shown in Table 2. 3.2.1. Dermatitis herpetiformis (DH) and NSCLC Mendelian Randomization (MR) analyses revealed a significant causal relationship between dermatitis herpetiformis (DH) and squamous cell carcinoma (SCC) of the lung. The analysis demonstrated robust associations with p-values: IVW P = 0.0782 × 10⁻⁴, MR-Egger P = 0.2778, Weighted Median (WM) P = 0.0004, Simple mode P = 0.0845, and Weighted mode P = 0.0258.

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

No heterogeneity was detected (Cochran's Q test P > 0.05), and the MR-Egger intercept test confirmed no significant pleiotropy (P = 0.6038). For adenocarcinoma (ADC), the causal association with DH was weaker, reflected in p-values: IVW P = 0.0357, MR-Egger P = 0.2920, WM P = 0.0737, Simple mode P = 0.1908, and Weighted mode P = 0.1946. Cochran's Q test for ADC showed no heterogeneity (P > 0.05), and the MR-Egger intercept test confirmed no significant pleiotropy (P = 0.6909). Leave-one-out analysis confirmed that no single SNP disproportionately influenced the results. Scatter plots visually confirmed the consistency and direction of these findings across all methods. (Fig. 2). 3.2.2. Acne (AC) and NSCLC Mendelian Randomization (MR) analyses indicated a specific association between acne (AC) and squamous cell carcinoma (SCC) of the lung. P-values across methods were: IVW P = 0.0321, MR-Egger P = 0.2506, Weighted Median (WM) P = 0.0612, Simple mode P = 0.1997, and Weighted mode P = 0.1852. Cochran's Q test (P > 0.05) confirmed no heterogeneity, and the MR-Egger intercept test (P = 0.4230) showed no significant pleiotropy, supporting the reliability of this association. No causal relationship was found between AC and adenocarcinoma (ADC) of the lung, with all methods yielding p-values greater than 0.05. Cochran's Q test (P > 0.05) and MR-Egger intercept test (P = 0.8928) confirmed no heterogeneity or pleiotropy, reinforcing the conclusion that AC is not related to ADC. Scatter plots visually depicted the causal relationship between AC and NSCLC (Fig. 3). 3.2.3. Hidradenitis suppurativa (HS) and NSCLC Mendelian Randomization (MR) analysis indicated a causal relationship between hidradenitis suppurativa (HS) and lung adenocarcinoma (ADC), supported by p-values: IVW P = 0.0260, MR-Egger P = 0.5434, Weighted Median (WM) P = 0.0590, Simple mode P = 0.2014, and Weighted mode P = 0.2244. Cochran's Q test (P > 0.05) indicated no heterogeneity, and the MR-Egger

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

intercept test (P = 0.7080) showed no significant pleiotropy, confirming the reliability of the HS-ADC association. No causal relationship was found between HS and squamous cell carcinoma (SCC) of the lung, with all methods yielding p-values greater than 0.05. The MR-Egger intercept test (P = 0.2834) confirmed no significant pleiotropy, though the IVW Q test for SCC showed heterogeneity (P = 0.0062). This heterogeneity is less concerning due to the overall negative results for SCC. Leaveone-out analysis identified a single SNP with significant impact, but removing it left only two instrumental variables, insufficient for robust analysis. Scatter plots visually depicted the causal relationship between HS and NSCLC (Fig. 4). 3.2.4. Rhinophyma (RHN) and NSCLC Mendelian Randomization (MR) analyses suggested a potential causal relationship between rhinophyma (RHN) and adenocarcinoma (ADC) of the lung, with p-values: IVW P = 0.0382, MR-Egger P = 0.7349, Weighted Median (WM) P = 0.1433, Simple mode P = 0.4288, and Weighted mode P = 0.2913. Cochran's Q test (P > 0.05) indicated no significant heterogeneity, and the MR-Egger intercept test (P = 0.7095) showed no significant pleiotropy. One SNP significantly impacted the results in the leave-one-out analysis, but only the IVW method retained a p-value below 0.05 after exclusion. No causal relationship was found between RHN and squamous cell carcinoma (SCC), with all methods yielding p-values greater than 0.05. Cochran's Q test (P > 0.05) and MR-Egger test (P = 0.4915) confirmed no heterogeneity or pleiotropy. Scatter plots illustrated these relationships (Fig. 5). The association between RHN and ADC should be interpreted with caution due to the reliance on a lowered significance threshold. 3.2.5. The remaining 15 skin conditions and NSCLC The remaining 15 skin conditions showed no association with the two types of NSCLC (all analysis methods P > 0.05). For datasets where the leave-one-out analysis revealed that certain SNPs interfered with the results, a new MR analysis was performed after removing the

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

corresponding SNPs. The analysis conducted after removing the corresponding SNPs still failed to yield positive results.

Discussion

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

In modern life sciences research, both the lungs and the skin originate from the mesoderm, indicating a shared homology in their growth and development [23]-[24]. Pathophysiological studies have further confirmed the connection between the two. For example, in mucosal immunity, secretory immunoglobulin A (slgA) serves as a key effector molecule. Research has shown its varying levels of expression in diseases such as asthma and chronic urticaria [25][26]. Some studies focusing on the relationship between immunity, inflammation, and malignancy have identified key pathways, including Toll-like receptors (TLRs) and the tumor microenvironment (TME), which share inflammatory signals with skin diseases. For instance, cytokines such as TNF-a, IL-6, and IL-1β play critical roles in both lung and skin inflammation, suggesting that there may be mechanistic overlaps between pulmonary and dermatological conditions [6]. In NSCLC, commonly used EGFR-TKI targeted drugs frequently cause skin rashes as the most common side effect. Current research on EGFR-TKI-related rashes suggests that the primary cause of these rashes is the disruption of the EGFR pathway, leading to interference with keratinocyte growth, migration, proliferation, and differentiation [27]. Recent MR studies on psoriasis and lung cancer published over the past two years [8]-[9] have bolstered our confidence in exploring this area further. Consequently, our team, building on these studies and leveraging the updated FinnGen R11 dataset from June 2024, selected 26 skin diseases as instrumental variables to investigate the relationship between skin diseases and nonsmall cell lung cancer. Regarding the four skin diseases that yielded positive results: Dermatitis herpetiformis, Acne. Hidradenitis suppurativa, and Rhinophyma. Dermatitis herpetiformis (DH) is characterized by blistering rashes, often accompanied by intense itching, and frequently co-occurs with celiac disease. Previous studies have identified a significant association between DH and the development of malignancies. A 2012 cohort study, with a 25-

year follow-up, concluded that DH was significantly linked to the incidence of visceral and lymphatic tumors [28]-[29]. However, few further in-depth studies have been conducted on this topic since then. For Acne, there are a few reports linking it with malignancies such as breast cancer and prostate cancer. However, no other studies have clearly elucidated the relationship between Acne and lung cancer [30]-[31]. Hidradenitis suppurativa (HS) has been associated with lymphoma [32] and skin malignancies in previous studies. Approximately 0.5% to 4.6% of HS patients have later been diagnosed with cutaneous squamous cell carcinoma [33]. Additionally, a systematic review encompassing 2,795 articles demonstrated an association between HS and psoriasis, indicating shared inflammatory pathways such as the IL-12-IL-23 axis, IL-17 interactions, and tumor necrosis factor (TNF)-α [34]. Previous studies have confirmed the association between psoriasis and the risk of lung cancer [8]-[9]. Therefore, the correlation between HS and NSCLC is supported by existing research. Rhinophyma is generally considered an advanced manifestation of Rosacea. Currently, research specifically on Rhinophyma is limited, but studies on Rosacea have confirmed its association with an increased risk of skin and breast malignancies, particularly showing a significant correlation with HER2-negative breast cancer [35]-[36]. The MR analysis provides new evidence on the relationship between four skin diseases (Dermatitis herpetiformis, Acne, Rhinophyma, and Hidradenitis suppurativa) and the risk of NSCLC. However, the study has limitations, To ensure the consistency of the study population, we can currently only choose data with a predominantly European population. Additionally, although the causal relationships were analyzed using genetic instrumental variables, the results show that, apart from Dermatitis herpetiformis, the other three skin diseases are only associated with one type of NSCLC. Further research is needed to understand the specific relationships and patterns between different skin diseases and NSCLC subtypes. In addition, after the relevant genomic studies are further refined, further studies in Asian populations are needed to compare the results with the present study.

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

Conclusion

254

255

256

257

258

259

260

261

262

263

264

265

267

269

271

This study confirms the association between four skin diseases and the risk of NSCLC. Dermatitis herpetiformis is significantly associated with an increased risk of squamous cell carcinoma of the lung. Acne shows a nominal association with an increased risk of squamous cell carcinoma of the lung. Rhinophyma, Hidradenitis suppurativa, and Dermatitis herpetiformis also exhibit nominal associations with an increased risk of adenocarcinoma of the lung. These findings provide direction for future clinical and experimental research related to NSCLC and highlight the importance of NSCLC screening and prevention in patients with these conditions. The fifteen skin diseases not found to be associated with NSCLC can help guide future research away from unrelated areas. Further genomic studies are necessary for the seven skin diseases for which sufficient SNP data were not obtained.

Acknowledgments

We thank FinnGen database for their contributions.

Data availability

The dataset in this study can be found in the FinnGen database.

Consent for publication

Not applicable.

Funding

- 272 This study was partially supported by the 2024 Traditional Chinese Medicine Research Program
- of Hunan Provincial Administration of Traditional Chinese Medicine (Grant Number: D2024032).

Competing interests

The author(s) report no conflicts of interest in this work.

References

274

276

281 282

283

284

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304 305

306

307 308

- 277 [1] Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of Incidence, Prevalence, Survival, and
 278 Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol. 2021
 279 Dec 1;7(12):1824-1832. doi: 10.1001/jamaoncol.2021.4932. PMID: 34673888; PMCID:
 280 PMC8532041.
 - [2] Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, Faramarzi F, Khorasani S, Alimohammadi M, Tahmasebi S, Akhavan-Sigari R. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023 Aug 11;23(1):162. doi: 10.1186/s12935-023-02990-y. PMID: 37568193; PMCID: PMC10416536.
- 285 [3] Rodak O, Peris-Díaz MD, Olbromski M, Podhorska-Okołów M, Dzięgiel P. Current Landscape 286 of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, 287 and Immunotherapy. Cancers (Basel). 2021 Sep 20;13(18):4705. doi: 288 10.3390/cancers13184705. PMID: 34572931; PMCID: PMC8470525.
 - [4] Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017 Jun;139(6):1723-1734. doi: 10.1016/j.jaci.2017.04.004. PMID: 28583445.
 - [5] Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007 May;117(5):1175-83. doi: 10.1172/JCI31537. PMID: 17476347; PMCID: PMC1857251.
 - [6] Subudhi I, Konieczny P, Prystupa A, Castillo RL, Sze-Tu E, Xing Y, Rosenblum D, Reznikov I, Sidhu I, Loomis C, Lu CP, Anandasabapathy N, Suárez-Fariñas M, Gudjonsson JE, Tsirigos A, Scher JU, Naik S. Metabolic coordination between skin epithelium and type 17 immunity sustains chronic skin inflammation. Immunity. 2024 Jul 9;57(7):1665-1680.e7. doi: 10.1016/j.immuni.2024.04.022. Epub 2024 May 20. PMID: 38772365; PMCID: PMC11236527.
 - [7] Budisan L, Zanoaga O, Braicu C, Pirlog R, Covaliu B, Esanu V, Korban SS, Berindan-Neagoe I. Links between Infections, Lung Cancer, and the Immune System. Int J Mol Sci. 2021 Aug 30;22(17):9394. doi: 10.3390/ijms22179394. PMID: 34502312; PMCID: PMC8431665.
 - [8] Luo Q, Chen J, Qin L, Luo Y, Zhang Y, Yang X, Wang H. Psoriasis may increase the risk of lung cancer: a two-sample Mendelian randomization study. J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2113-2119. doi: 10.1111/jdv.18437. Epub 2022 Jul 28. PMID: 35844064.
 - [9] Wang X, Wang X, Wang H, Yang M, Dong W, Shao D. Association between psoriasis and lung cancer: two-sample Mendelian randomization analyses. BMC Pulm Med. 2023 Jan 5;23(1):4. doi: 10.1186/s12890-022-02297-0. PMID: 36604675; PMCID: PMC9814449.
- [10] Fyhrquist N, Muirhead G, Prast-Nielsen S, Jeanmougin M, Olah P, Skoog T, Jules-Clement G, 310 311 Feld M. Barrientos-Somarribas M. Sinkko H. van den Bogaard EH, Zeeuwen PLJM, Rikken G. Schalkwijk J, Niehues H, Däubener W, Eller SK, Alexander H, Pennino D, Suomela S, Tessas 312 I, Lybeck E, Baran AM, Darban H, Gangwar RS, Gerstel U, Jahn K, Karisola P, Yan L, 313 Hansmann B, Katayama S, Meller S, Bylesjö M, Hupé P, Levi-Schaffer F, Greco D, Ranki A, 314 315 Schröder JM, Barker J, Kere J, Tsoka S, Lauerma A, Soumelis V, Nestle FO, Homey B, 316 Andersson B, Alenius H. Microbe-host interplay in atopic dermatitis and psoriasis. Nat Commun. 317 2019 Oct 16;10(1):4703. doi: 10.1038/s41467-019-12253-y. PMID: 31619666; PMCID: PMC6795799. 318
- 319 [11] Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, 320 Popat UR, Shpall EJ, Champlin RE, Oran B. Significance of minimal residual disease 321 monitoring by real-time quantitative polymerase chain reaction in core binding factor acute 322 myeloid leukemia for transplantation outcomes. Cancer. 2020 May 15;126(10):2183-2192. doi:

323 10.1002/cncr.32769. Epub 2020 Feb 26. PMID: 32101640.

324

325

326

327

328 329

330

331

332

333

334

335

336

337

338

339340

341

342

343

344

345

346 347

348

349

350

351 352

353

354 355

356

357

358 359

360 361

362

363 364

365366

367

368 369

370

371

- [12] P. Sekula, M.F. Del Greco, C. Pattaro, et al., Mendelian randomization as an approach to assess causality using observational data, J. Am. Soc. Nephrol. 27 (11) (2016) 3253–3265, https://doi.org/10.1681/ASN.2016010098.
 - [13] L. Li, Q. Ren, Q. Zheng, et al., Causal associations between gastroesophageal reflux disease and lung cancer risk: a Mendelian randomization study, Cancer Med. 12 (6) (2023) 7552–7559, https://doi.org/10.1002/cam4.5498.
 - [14] K. Lee, C.Y. Lim, Mendelian randomization analysis in observational epidemiology, J Lipid Atheroscler 8 (2) (2019) 67–77, https://doi.org/10.12997/jla.2019.8.2.67.
- [15] E. Birney, Mendelian randomization, Cold Spring Harb Perspect Med. 12 (4) (2022) a041302, https://doi.org/10.1101/cshperspect.a041302.
- [16] J.A. de Klerk, J.W.J. Beulens, H.L. Mei, et al., Altered blood gene expression in the obesity-related type 2 diabetes cluster may be causally involved in lipid metabolism:a Mendelian randomization study, Diabetologia 66 (6) (2023) 1057–1070, https://doi.org/10.1007/s00125-023-05886-8.
- [17] Xu L, Li H, Liu B, Han X, Sun H. Systemic Inflammatory Regulators Associated with Osteoporosis: A Bidirectional Mendelian Randomization Study. Calcif Tissue Int. 2024 May;114(5):490-501. doi: 10.1007/s00223-024-01200-9. Epub 2024 Mar 25. PMID: 38528199.
- [18] J. Bowden, M.F. Del Greco, C. Minelli, et al., Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic, Int. J. Epidemiol. 45 (6) (2016) 1961–1974, https://doi. org/10.1093/ije/dyw220.
- [19] S. Burgess, S.G. Thompson, Interpreting findings from Mendelian randomization using the MR-Egger method, Eur. J. Epidemiol. 32 (5) (2017) 377–389, https://doi. org/10.1007/s10654-017-0255-x.
- [20] J. Bowden, G. Davey Smith, S. Burgess, Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression, Int. J. Epidemiol. 44 (2) (2015) 512–525, https://doi.org/10.1093/ije/dyv080.
- [21] Fife JD, Cassa CA. Estimating clinical risk in gene regions from population sequencing cohort data. Am J Hum Genet. 2023 Jun 1;110(6):940-949. doi: 10.1016/j.ajhg.2023.05.003. Epub 2023 May 25. PMID: 37236177; PMCID: PMC10257006.
- [22] Fife JD, Cassa CA. Estimating clinical risk in gene regions from population sequencing cohort data. Am J Hum Genet. 2023 Jun 1;110(6):940-949. doi: 10.1016/j.ajhg.2023.05.003. Epub 2023 May 25. PMID: 37236177; PMCID: PMC10257006.
- [23] Chinoy MR. Lung growth and development. Front Biosci. 2003 Jan 1;8:d392-415. doi: 10.2741/974. PMID: 12456356.
- [24] Visscher M, Narendran V. The Ontogeny of Skin. Adv Wound Care (New Rochelle). 2014 Apr 1;3(4):291-303. doi: 10.1089/wound.2013.0467. PMID: 24761361; PMCID: PMC3985523.
- [25] de Fays C, Carlier FM, Gohy S, Pilette C. Secretory Immunoglobulin A Immunity in Chronic Obstructive Respiratory Diseases. Cells. 2022 Apr 13;11(8):1324. doi: 10.3390/cells11081324. PMID: 35456002; PMCID: PMC9027823.
- [26] Corthésy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol. 2013 Jul 12;4:185. doi: 10.3389/fimmu.2013.00185. PMID: 23874333; PMCID: PMC3709412.
- [27] Chen C B, Wu M Y, Ng C Y, et al. Severe cutaneous adverse reactions induced by ta rgeted anticancer therapies and immunotherapies[J]. Cancer Manag Res, 2018,10:1 259-1273.
- [28] Sneddon IB. Cutaneous manifestations of visceral malignancy. Postgrad Med J. 1970 Nov;46(541):678-85. doi: 10.1136/pgmj.46.541.678. PMID: 4924274; PMCID: PMC2467095.
- [29] Grainge MJ, West J, Solaymani-Dodaran M, Card TR, Logan RF. The long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study. Aliment Pharmacol Ther. 2012 Mar;35(6):730-9. doi: 10.1111/j.1365-2036.2012.04998.x. Epub 2012 Jan 30. PMID: 22288441.
- [30] Ugge H, Udumyan R, Carlsson J, Andrén O, Montgomery S, Davidsson S, Fall K. Acne in late
 adolescence and risk of prostate cancer. Int J Cancer. 2018 Apr 15;142(8):1580-1585. doi:
 10.1002/ijc.31192. Epub 2017 Dec 14. PMID: 29205339; PMCID: PMC5838533.
- 376 [31] Murphy JD, Sandler D, White AJ, O'Brien KM. Severe acne and risk of breast cancer. Breast Cancer Res Treat. 2019 Sep;177(2):487-495. doi: 10.1007/s10549-019-05302-z. Epub 2019

- Jun 5. PMID: 31165375; PMCID: PMC6771926.
- [32] Tannenbaum R, Strunk A, Garg A. Association Between Hidradenitis Suppurativa and Lymphoma. JAMA Dermatol. 2019 May 1;155(5):624-625. doi: 10.1001/jamadermatol.2018.5230. PMID: 30698627; PMCID: PMC6506877.
- [33] Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S27-35. doi: 10.1016/j.jaad.2015.07.055. PMID: 26470611.
- [34] Gau SY, Preclaro IAC, Wei JC, Lee CY, Kuan YH, Hsiao YP, Juang SE, Ma KS. Risk of psoriasis in people with hidradenitis suppurativa: A systematic review and meta-analysis. Front Immunol. 2022 Dec 1;13:1033844. doi: 10.3389/fimmu.2022.1033844. PMID: 36532043; PMCID: PMC9752046.
- [35] Luo M, Wei B. Novel insights into rosacea's role in cancer risk: A Mendelian randomization approach. Skin Res Technol. 2024 May;30(5):e13737. doi: 10.1111/srt.13737. PMID: 38769705: PMCID: PMC11106556.
- [36] Li WQ, Zhang M, Danby FW, Han J, Qureshi AA. Personal history of rosacea and risk of incident cancer among women in the US. Br J Cancer. 2015 Jul 28;113(3):520-3. doi: 10.1038/bjc.2015.217. Epub 2015 Jun 23. PMID: 26103573; PMCID: PMC4522627.

Table 1

378

379

380

381

382

383 384

385

386

387 388

389

390 391

392

393

394

395

396

397

- The information on skin diseases and non-small cell lung cancer data used in this study, all of which can be obtained from the FinnGen database, includes the following:
- 399 Lung Cancers: Lung Squamous Cell Carcinoma (SCC), Lung Adenocarcinoma (ADC),
- Skin Diseases: Acne (AC), Hidradenitis Suppurativa (HS), Dermatitis Herpetiformis (DH),
- 401 Infective Dermatitis (ID), Localized Scleroderma (LS), Cutaneous Abscess, Furuncle, and
- Carbuncle (CA), Atrophic Disorders of Skin (ADS), Papulosquamous Disorders (PSD), Atopic
- 403 Dermatitis (AD), Urticaria (URT), Rhinophyma (RHN), Acquired Keratosis Palmaris et Plantaris
- 404 (AKD), Pityriasis Lichenoides Chronica (PLC), Pityriasis Rosea (PR), Pyoderma (PYD), Xerosis
- 405 Cutis (XER), Pruritus (PRU), Pemphigus (PEM), Seborrhoeic Dermatitis (SD), Pityriasis Rubra
- Pilaris (PRP), Lichen Planopilaris (LPP), Acne Conglobata (ACC), Erythema Multiforme (EM),
- Lupus Erythematosus (SLE), Chloasma (CHL), and Pigmented Purpuric Dermatosis (PPD).

Trait	N.cases	N.controls	Populations	Year	Filtering threshold
SCC	1787	345118	European	2024	-
ADC	2064	345118	European	2024	-
AC	3982	432686	European	2024	P < 5 × 10 ⁻⁸
HS	1209	432686	European	2024	P < 5 × 10 ⁻⁸
DH	585	451899	European	2024	P < 5 × 10 ⁻⁸
ID	4195	394476	European	2024	P < 5 × 10 ⁻⁸
LS	450	423041	European	2024	P < 5 × 10 ⁻⁸

CA	10296	426987	European	2024	P < 5 × 10 ⁻⁸
ADS	5037	423041	European	2024	P < 5 × 10 ⁻⁸
PSD	16313	437420	European	2024	P < 5 × 10 ⁻⁸
AD	26905	394476	European	2024	P < 5 × 10 ⁻⁸
URT	12576	438050	European	2024	P < 5 × 10 ⁻⁸
RHN	175	432686	European	2024	$P < 5 \times 10^{-6}$
AKD	137	423041	European	2024	$P < 5 \times 10^{-6}$
PLC	122	437420	European	2024	P < 5 × 10 ⁻⁶
PR	242	437420	European	2024	$P < 5 \times 10^{-6}$
PYD	643	426987	European	2024	P < 5 × 10 ⁻⁶
XER	429	423041	European	2024	$P < 5 \times 10^{-6}$
PRU	3819	394476	European	2024	$P < 5 \times 10^{-6}$
PEM	208	451899	European	2024	$P < 5 \times 10^{-6}$
SD	3382	394476	European	2024	$P < 5 \times 10^{-6}$
PRP	71	437420	European	2024	Insufficient data
LPP	83	432686	European	2024	Insufficient data
ACC	175	432686	European	2024	Insufficient data
EM	754	438050	European	2024	Insufficient data
SLE	777	423041	European	2024	Insufficient data
CHL	127	423041	European	2024	Insufficient data
PPD	289	423041	European	2024	Insufficient data

Table 2

408

409

410

Pleiotropy and heterogeneity test of the MR positive results, including Dermatitis herpetiformis (DH),

Acne (AC), Hidradenitis suppurativa (HS), and Rhinophyma (RHN). Lung Squamous Cell

411 Carcinoma (SCC) and adenocarcinoma of the lung (ADC)


Exposure	Outcome	Hete	Pleiotropy	
		MR Egger Q	IVW Q	Egger intercept
		(P)	(P)	(P)
DH	SCC	4.6051	4.9693	0.6038
		(0.3302)	(0.4196)	
AC		2.0474	2.9035	0.4230
		(0.5626)	(0.5740)	
HS		1.8801	10.1380	0.2834
		(0.1703)	(0.0062)	
RHN		0.4662	1.1637	0.4915
		(0.7920)	(0.7617)	

DH	ADC	4.5910	4.8008	0.6909
		(0.3318)	(0.4406)	
AC		0.9011	0.9226	0.8928
		(0.8251)	(0.9212)	
HS		0.0235	0.2673	0.7080
		(0.8779)	(0.8748)	
RHN		1.9837	2.1679	0.7095
		(0.3708)	(0.5382)	


Table 3

412

- 414 MR analysis results of skin diseases with positive associations and non-small cell lung cancer,
- including Dermatitis herpetiformis (DH), Acne (AC), Hidradenitis suppurativa (HS), and
- Rhinophyma (RHN), with Lung Squamous Cell Carcinoma (SCC) and adenocarcinoma of the
- 417 lung (ADC).



420 **Figure 1**. The flowchart of the study.






Figure. 2. Dermatitis herpetiformis and NSCLC (SCC left ADC right)




Figure. 3. Acne and NSCLC (SCC left ADC right)

424

425




Figure. 4. Hidradenitis suppurativa and NSCLC (SCC left ADC right)





Figure. 5. Rhinophyma and NSCLC (SCC left ADC right)

Obtain datasets for skin diseases (exposure) and lung squamous cell carcinoma; lung adenocarcinoma (outcome) from the FinnGen

Select appropriate genetic instrumental variables (GIVs) for skin diseases (p<5×10^-8, r^2<0.001, window size=10000kb, minor allele frequency MAF > 0.01; removal of SNPs associated with non-small cell lung cancer. If sufficient SNPs cannot be obtained under the p<5×10^-8 threshold, the standard will be relaxed to p<5×10^-6).



DH and AC \xrightarrow{risk} SCC DH,HS and RHN \xrightarrow{risk} ADC

15 skin diseases showed no statistically significant association with NSCLC